Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details about recent executive changes within the company.
Saviuk announced the appointment of Pascal Tougas as the new chief financial officer, succeeding Luc Mainville.
Tougas is recognized as a well-experienced senior executive in the pharmaceutical industry, with a robust financial background. His previous tenure at Sanofi Canada for 11 years saw him in various key roles, including Country Head, Trade and Revenue Management, interim Chief Financial Officer Canada, and Director Controlling and Operations Canada, among others.
Pascal is also well-qualified academically, holding a bachelor's degree in business administration from HEC Montreal along with a CPA designation.
Additionally, Saviuk informed Proactive about Valeo Pharma’s strategic efforts aimed at reducing operational costs as the company advances towards profitability. One significant move in this direction is the realignment of the company’s organizational structure. This realignment is expected to yield cost savings while enhancing the efficiency and timeliness of decision-making within the company. These changes are projected to save the company over $2 million.
Proactive
+1 347-449-0879
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$0.11 |
Daily Volume: | 0 |
Market Cap: | C$10.360M |
June 13, 2024 March 14, 2024 February 13, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB